The new, “Standard” versions of the company’s Model Y and Model 3 vehicles will start at $39,990 and $36,990 respectively.The new, “Standard” versions of the company’s Model Y and Model 3 vehicles will start at $39,990 and $36,990 respectively.

Tesla Rolls Out Cheaper EVs, But Prices Fail to Excite Market

2025/10/09 15:53
Okuma süresi: 1 dk

Tesla debuted cheaper versions of its best-selling Model Y and Model 3 vehicles Tuesday in a bid to capture lost market share, Reuters reported.

The new, “Standard” versions of the company’s Model Y and Model 3 vehicles will start at $39,990 and $36,990 respectively, and offer ranges of above 300 miles, the report said.

The new, lower price points are intended to attract a wider base of customers — a long-standing goal of CEO Elon Musk — but were met with a lukewarm response from market observers.

Investors are concerned that the prices are not low enough to significantly boost demand, while analysts noted that the new prices may not be competitive enough to sway buyers from an increasing number of lower-cost alternatives, particularly in key overseas markets such as China and Europe.

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

CEO Sandeep Nailwal Shared Highlights About RWA on Polygon

CEO Sandeep Nailwal Shared Highlights About RWA on Polygon

The post CEO Sandeep Nailwal Shared Highlights About RWA on Polygon appeared on BitcoinEthereumNews.com. Polygon CEO Sandeep Nailwal highlighted Polygon’s lead in global bonds, Spiko US T-Bill, and Spiko Euro T-Bill. Polygon published an X post to share that its roadmap to GigaGas was still scaling. Sentiments around POL price were last seen to be bearish. Polygon CEO Sandeep Nailwal shared key pointers from the Dune and RWA.xyz report. These pertain to highlights about RWA on Polygon. Simultaneously, Polygon underlined its roadmap towards GigaGas. Sentiments around POL price were last seen fumbling under bearish emotions. Polygon CEO Sandeep Nailwal on Polygon RWA CEO Sandeep Nailwal highlighted three key points from the Dune and RWA.xyz report. The Chief Executive of Polygon maintained that Polygon PoS was hosting RWA TVL worth $1.13 billion across 269 assets plus 2,900 holders. Nailwal confirmed from the report that RWA was happening on Polygon. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 The X post published by Polygon CEO Sandeep Nailwal underlined that the ecosystem was leading in global bonds by holding a 62% share of tokenized global bonds. He further highlighted that Polygon was leading with Spiko US T-Bill at approximately 29% share of TVL along with Ethereum, adding that the ecosystem had more than 50% share in the number of holders. Finally, Sandeep highlighted from the report that there was a strong adoption for Spiko Euro T-Bill with 38% share of TVL. He added that 68% of returns were on Polygon across all the chains. Polygon Roadmap to GigaGas In a different update from Polygon, the community…
Paylaş
BitcoinEthereumNews2025/09/18 01:10
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion
Paylaş
AI Journal2026/02/25 21:36
How BlackRock and JPMorgan Are Quietly Building On Blockchain - Institutional DeFi Is Here

How BlackRock and JPMorgan Are Quietly Building On Blockchain - Institutional DeFi Is Here

read more
Paylaş
Coinstats2025/09/18 19:43